On September 11, 2023 the FDA decided to authorise under “emergency use” the “updated mRNA vaccines for 2023-2024 manufactured by ModernaTX Inc. and Pfizer Inc.” which includes a “monovalent (single) component that corresponds to the Omicron variant XBB.1.5.” The purposed being to “better protect against crrently circulating variants” for all ages from 6 months of age, “to provide better protection against serious consequences of COVID-19, including hospitalization and death.” [1, 2]
This is based on the “FDA’s evaluation of manufacturing data to support the change”. The FDA’s expert advisors (VRBPAC) decided back in June 15, 2023 on recommendations for “SARS-CoV-2 strain(s) for updated COVID-19 vaccines.”
“The updated mRNA vaccines are each approved for individuals 12 years of age and older and are authorized under emergency use for individuals 6 months through 11 years of age.” It has only been tested on mice and is determined safe for as young as 6 month old children!